Impact of Tirzepatide on diet-related quality of life and treatment satisfaction in people with type 2 diabetes mellitus: a retrospective cross-sectional study.

Kato S, Kokita A, Akanuma H, Iwamura S, Takahashi Y, Kusumi R, Abe S, Sasaki K, Otomo H, Ando S, Nara M, Nara A and 7 more

Show all authors

Tadika T, Shimizu T, Sato T, Morii T, Fujita H, Matsuda D, Waki H

Diabetes research and clinical practice20 Sept 2025

PMID40983113DOI10.1016/j.diabres.2025.112913PepBankPUB-40983113

Publisher page PubMedAsk about this study

Jump to 5 results

Summary

AimsTo explore how Tirzepatide (TZP) treatment influences diet-related quality of life (QoL) and thus treatment satisfaction.MethodsThis retrospective observational study analyzed 95 people with type 2 diabetes mellitus treated with TZP. We evaluated measurements before and after TZP treatment for clinical parameters (including BMI and HbA1c) and, via validated questionnaires, patient-reported treatment satisfaction and diet-related QoL (including the Diabetes Diet-Related Quality of Life-Revised 9 (DDRQOL-R-9)). We used Spearman correlations and multiple regression analyses to identify predictors of treatment satisfaction.ResultsTZP treatment led to significant reduction of median HbA1c (7.4 % to 6.4 %) and body weight (77.2 kg to 70.6 kg). Median diet-related QoL, specifically the "perceived merits of dietary therapy", increased from 58.3 [IQR 50.0, 75.0] to 67.7 [50.0, 83.3] (p < 0.01). Multiple regression analysis identified changes in BMI (standardized β = - 0.21, p = 0.030) and changes in diet-related QoL "perceived merits of dietary therapy" (β = 0.23, p = 0.019) as independent predictors of DTSQs scores post-TZP treatment.ConclusionDespite TZP's appetite-suppressing effects, diet-related QoL, particularly the "perceived merits of dietary therapy", significantly increased with treatment, serving as an independent and substantial contributor to patient satisfaction, comparable to the impact of body weight reduction.

CC BYText from Europe PMC. Highlighted sentences are the source of results.

Results from this study5

5 results from studies that gave the peptide. 5 results from people.

01HumanObservational studyEfficacy outcome
In people with type 2 diabetes, median HbA1c fell from 7.4% to 6.4% after tirzepatide treatment.
In plain wordsIn people with type 2 diabetes, HbA1c was lower after tirzepatide treatment (7.4% before, 6.4% after).
Peptide
Tirzepatide
Outcome
DecreaseMedian HbA1c change
Study
n = 95
Outcome group
Glycemic control · Metabolic and weight
Studied dose
Dose not stated
Measurements
Median HbA1c before
7.4%
baseline
Median HbA1c after
6.4%
after tirzepatide
Source sentences
Summary
TZP treatment led to significant reduction of median HbA1c (7.4 % to 6.4 %) and body weight (77.2 kg to 70.6 kg).
1 context sentence(design, population, supporting numbers)
Summary · context
This retrospective observational study analyzed 95 people with type 2 diabetes mellitus treated with TZP.
Show in the study text Report a problemFND-4098311301
02HumanObservational studyEfficacy outcome
In people with type 2 diabetes, median body weight fell from 77.2 kg to 70.6 kg after tirzepatide treatment.
In plain wordsIn people with type 2 diabetes, body weight was lower after tirzepatide treatment (77.2 kg before, 70.6 kg after).
Peptide
Tirzepatide
Outcome
DecreaseMedian body weight change
Study
n = 95
Outcome group
Body weight · Metabolic and weight
Studied dose
Dose not stated
Measurements
Median body weight before
77.2 kg
baseline
Median body weight after
70.6 kg
after tirzepatide
Source sentences
Summary
and body weight (77.2 kg to 70.6 kg).
1 context sentence(design, population, supporting numbers)
Summary · context
This retrospective observational study analyzed 95 people with type 2 diabetes mellitus treated with TZP.
Show in the study text Report a problemFND-4098311302
03HumanObservational studyEfficacy outcome
In people with type 2 diabetes, the median diet-related quality-of-life score for perceived merits of dietary therapy rose from 58.3 to 67.7 after tirzepatide treatment.
In plain wordsIn people with type 2 diabetes, scores for the perceived merits of dietary therapy were higher after tirzepatide treatment.
Peptide
Tirzepatide
Outcome
IncreaseDiet-related QoL, perceived merits of dietary therapy
Study
n = 95
Outcome group
Quality of life · Whole body
Studied dose
Dose not stated
Measurements
Median score before
58.3 points
baseline
Median score after
67.7 points
after tirzepatide
Source sentences
Summary
Median diet-related QoL, specifically the "perceived merits of dietary therapy", increased from 58.3 [IQR 50.0, 75.0] to 67.7 [50.0, 83.3] (p < 0.01).
1 context sentence(design, population, supporting numbers)
Summary · context
This retrospective observational study analyzed 95 people with type 2 diabetes mellitus treated with TZP.
Show in the study text Report a problemFND-4098311303
04HumanObservational studyEfficacy outcome
In people with type 2 diabetes treated with tirzepatide, change in BMI was an independent predictor of treatment satisfaction scores.
In plain wordsIn people with type 2 diabetes taking tirzepatide, change in BMI was linked to how satisfied they were with treatment.
Peptide
Tirzepatide
Outcome
Not applicableChange in BMI as predictor of treatment satisfaction
Study
n = 95
Outcome group
Quality of life · Whole body
Studied dose
Dose not stated
Measurements
Standardized beta
−0.21
change in BMI
Source sentences
Summary
Multiple regression analysis identified changes in BMI (standardized β = - 0.21, p = 0.030) and changes in diet-related QoL "perceived merits of dietary therapy" (β = 0.23, p = 0.019) as independent predictors of DTSQs scores post-TZP treatment.
1 context sentence(design, population, supporting numbers)
Summary · context
This retrospective observational study analyzed 95 people with type 2 diabetes mellitus treated with TZP.
Show in the study text Report a problemFND-4098311304
05HumanObservational studyEfficacy outcome
In people with type 2 diabetes treated with tirzepatide, change in the perceived merits of dietary therapy was an independent predictor of treatment satisfaction scores.
In plain wordsIn people with type 2 diabetes taking tirzepatide, a rise in perceived merits of dietary therapy was linked to higher treatment satisfaction.
Peptide
Tirzepatide
Outcome
Not applicableChange in diet-related QoL as predictor of treatment satisfaction
Study
n = 95
Outcome group
Quality of life · Whole body
Studied dose
Dose not stated
Measurements
Beta
0.23
perceived merits of dietary therapy
Source sentences
Summary
and changes in diet-related QoL "perceived merits of dietary therapy" (β = 0.23, p = 0.019)
1 context sentence(design, population, supporting numbers)
Summary · context
This retrospective observational study analyzed 95 people with type 2 diabetes mellitus treated with TZP.
Show in the study text Report a problemFND-4098311305

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
12 Oct 2026, 12:58 UTC
Study results updated
Version 1
9 Oct 2026, 03:07 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

Keywords

PepBank is a research reference. Talk to a doctor before you use any peptide.